Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Cancer Type/Condition:  childhood astrocytoma
Stage/Subtype:  childhood astrocytoma
Country:  U.S.A.
Trial Type:  Treatment
Results 1-25 of 35 for your search:
Start Over
Combination Chemotherapy and Fixed or Flexible Administration of Filgrastim in Treating Younger Patients With Cancer
Status: Active
Phase: Phase III
Type: Treatment
Age: 1 to 25
Trial IDs: 2013-062, NCI-2013-02001, NCT01987596
Carboplatin with or without Vincristine Sulfate in Treating Younger Patients with Previously Untreated Low Grade Glioma
Status: Active
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 21 and younger
Trial IDs: LCH 14C03, NCI-2015-01146, 2014-15932, LGG-14C03, NCT02455245
Vorinostat and Etoposide in Treating Younger Patients With Refractory or Relapsed Solid Tumors
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 4 to 21
Trial IDs: 10-096, NCI-2011-00493, NCT01294670
Study of IDO Inhibitor and Temozolomide for Adult Patients With Primary Malignant Brain Tumors
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 16 and over
Trial IDs: NLG2102, NCI-2014-02063, NCT02052648
Multitargeted Tyrosine Kinase Inhibitor PLX3397 in Treating Younger Patients with Refractory Leukemias or Solid Tumors
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 3 to 30
Trial IDs: 15-C-0093, NCI-2015-00457, 150093, P141640, NCT02390752
Iodine I 131 Monoclonal Antibody 3F8 in Treating Patients with GD2-Expressing Central Nervous System and Leptomeningeal Neoplasms
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: Any age
Trial IDs: 05-122, NCI-2016-00874, MSKCC-05122, NCT00445965
Valproic Acid and Radiation Therapy Followed by Maintenance Valproic Acid and Bevacizumab in Treating Young Patients With Newly Diagnosed High-Grade Gliomas
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 3 to 21
Trial IDs: H-24549, NCI-2012-00618, NCT00879437
Everolimus in Treating Younger Patients With Neurofibromatosis Type 1 or Low Grade Gliomas That Did Not Responded to Chemotherapy
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 1 to 21
Trial IDs: 09452, NCI-2010-01929, DOD W81XWH-05-1-0615, NCT01158651
Poly ICLC in Treating Younger Patients With Recurrent or Progressive Low Grade Gliomas
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 0 to 21
Trial IDs: Poly-ICLC, NCI-2013-02084, NCT01188096
Proton Beam Radiation Therapy in Treating Younger Patients with Brain Tumors
Status: Active
Phase: Phase II
Type: Natural history/Epidemiology, Treatment
Age: 1 to 25
Trial IDs: 10-206, NCI-2011-00201, NCT01288235
Everolimus in Treating Younger Patients With Recurrent or Progressive Low-Grade Gliomas
Status: Active
Phase: Phase II
Type: Tissue collection/Repository, Treatment
Age: 3 to 21
Trial IDs: 120817, NCI-2012-02774, PNOC001, NCT01734512
Peginterferon alfa-2b in Treating Younger Patients with Recurrent or Refractory and Radiographically or Clinically Progressive Pilocytic Astrocytomas and Optic Pathway Gliomas
Status: Active
Phase: Phase II
Type: Treatment
Age: 3 to 18
Trial IDs: CHOA2725-14, NCI-2015-00181, IRB00074563, NCT02343224
Vaccine Therapy and Poly-ICLC in Treating Younger Patients with Recurrent Low-Grade Gliomas that Cannot Be Removed by Surgery
Status: Active
Phase: Phase II
Type: Treatment
Age: 12 months to less than 22 years
Trial IDs: LGG Vaccine Trial, NCI-2016-00644, NCT02358187
Erlotinib Hydrochloride and Temozolomide in Treating Younger Patients with Relapsed, Recurrent, or Refractory Solid Tumors
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 1 to 21
Trial IDs: 201604002, NCI-2016-00549, NCT02689336
Iodine I 131 Monoclonal Antibody 8H9 in Treating Patients with Recurrent or Refractory Tumors in the Brain and/or Spinal Cord
Status: Active
Phase: Phase I
Type: Treatment
Age: Any age
Trial IDs: 03-133, NCI-2016-00928, MSKCC-03133, NCT00089245
Crizotinib and Dasatinib in Treating Younger Patients with Recurrent or Progressive Diffuse Intrinsic Pontine Glioma or High-Grade Glioma
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 2 to 21
Trial IDs: SJHG12, NCI-2012-01240, NCT01644773
Palbociclib Isethionate in Treating Younger Patients with Recurrent, Progressive, or Refractory Central Nervous System Tumors
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 4 to 21
Trial IDs: PBTC-042, NCI-2014-00640, NCT02255461
Selinexor in Treating Younger Patients with Recurrent or Refractory Solid Tumors or High-Grade Gliomas
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 1 to 21
Trial IDs: ADVL1414, NCI-2014-02410, NCT02323880
Phase I Trial of Afatinib in Pediatric Tumours
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 2 to 17
Trial IDs: 1200.120, NCI-2016-00936, 2014-002123-10, NCT02372006
Pomalidomide in Treating Younger Patients with Recurrent, Progressive or Refractory Central Nervous System Tumors
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 3 to 20
Trial IDs: PBTC-043, NCI-2014-02182, CC-4047-PBTC-043, PPBTC-043_R04PAPP01, NCT02415153
Vorinostat and Temsirolimus with or without Radiation Therapy in Treating Younger Patients with Newly Diagnosed or Progressive Diffuse Intrinsic Pontine Glioma
Status: Active
Phase: Phase I
Type: Treatment
Age: 6 months to 21 years
Trial IDs: 2014-0135, NCI-2015-00817, NCT02420613
Wild-Type Reovirus in Combination with Sargramostim in Treating Younger Patients with High-Grade Recurrent or Refractory Brain Tumors
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 10 to 21
Trial IDs: MC1472, NCI-2015-00665, MC1472 / Mayo IRB 14-006414, Mod14-006414-01, NCT02444546
Ramucirumab in Treating Younger Patients with Recurrent or Refractory Solid Tumors, Including CNS Tumors
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 1 to 21
Trial IDs: ADVL1416, NCI-2015-00744, NCT02564198
Study of the IDO Pathway Inhibitor, Indoximod, and Temozolomide for Pediatric Patients With Progressive Primary Malignant Brain Tumors
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 3 to 21
Trial IDs: NLG2105, NCI-2015-01872, NCT02502708
Start Over